JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

MLA

Stebbing, Justin, et al. “JAK Inhibition Reduces SARS-CoV-2 Liver Infectivity and Modulates Inflammatory Responses to Reduce Morbidity and Mortality.” Science Advances, vol. 7, no. 1, Jan. 2021. EBSCOhost, https://doi.org/10.1126/sciadv.abe4724.

APA

Stebbing, J., Sánchez Nievas, G., Falcone, M., Youhanna, S., Richardson, P., Ottaviani, S., Shen, J. X., Sommerauer, C., Tiseo, G., Ghiadoni, L., Virdis, A., Monzani, F., Rizos, L. R., Forfori, F., Avendaño Céspedes, A., De Marco, S., Carrozzi, L., Lena, F., Sánchez-Jurado, P. M., … Lauschke, V. M. (2021). JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Science Advances, 7(1). https://doi.org/10.1126/sciadv.abe4724

Chicago

Stebbing, Justin, Ginés Sánchez Nievas, Marco Falcone, Sonia Youhanna, Peter Richardson, Silvia Ottaviani, Joanne X Shen, et al. 2021. “JAK Inhibition Reduces SARS-CoV-2 Liver Infectivity and Modulates Inflammatory Responses to Reduce Morbidity and Mortality.” Science Advances 7 (1). doi:10.1126/sciadv.abe4724.